Aripiprazole is a dopamine D2 receptor partial agonist undergoing evaluation as a pharmacotherapy for stimulant-use disorders. Acutely administered aripiprazole attenuates the discriminative stimulus and other behavioral effects of d-amphetamine in humans; however, whether aripiprazole attenuates the effects of more commonly abused stimulants is unknown. The aim of this experiment was to assess the discriminative stimulus, subject-rated and cardiovascular effects of oral cocaine alone and following acute administration of aripiprazole in humans. Eight cocaine-dependent subjects learned to discriminate 150 mg cocaine from placebo. After acquiring the discrimination, the effects of cocaine (0, 25, 50, 100 and 200 mg) administered alone and in combination with aripiprazole (15 mg) were determined. Significant effects of cocaine were observed for the drug discrimination task, stimulant-like subject-rated effects and heart rate. Limited effects of aripiprazole were revealed. However, for most measures, fewer doses of cocaine were significantly greater than placebo when combined with aripiprazole, suggesting a reduction in the discriminative stimulus, self-reported and cardiovascular effects of cocaine. These data are consistent with previous studies that have tested acutely administered aripiprazole in combination with d-amphetamine and suggest that the ability of aripiprazole to modify stimulant effects is a function of the duration of treatment (acute vs. chronic).
AngristBCorwinJBartlikBCooperT (1987) Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry22: 1357–1368.
2.
BarrettRLAppelJB (1989) Effects of stimulation and blockade of dopamine receptor subtypes on the discriminative stimulus properties of cocaine. Psychopharmacology99: 13–16.
3.
BergmanJ (2008) Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify). Exp Clin Psychopharmacol16: 475–483.
4.
BoultonDWKolliaGMallikaarjunSKomoroskiBSharmaAKovalickLJ (2008) Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet47: 475–485.
5.
CaineSBNegusSSMelloNKBergmanJ (2000) Effects of dopamine D1-like and D2-like agonists in rats trained to discriminate cocaine from saline: Influence of experimental history. Exp Clin Psychopharmacol8: 404–414.
6.
CallahanPMCunninghamKA (1993) Discriminative stimulus properties of cocaine in relation to dopamine D2 receptor function in rats. J Pharmacol Exp Ther266: 585–592.
7.
CallahanPMCunninghamKA (1997) Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists. Neuropharmacology36: 373–381.
8.
CallahanPMAppelJBCunninghamKA (1991) Dopamine D1 and D2 mediation of the discriminative stimulus properties of d-amphetamine and cocaine. Psychopharmacology103: 50–55.
9.
ChaitLDUhlenhuthEHJohansonCE (1985) The discriminative stimulus and subjective effects of d-amphetamine in humans. Psychopharmacology86: 307–312.
10.
ChildressARO’BrienCP (2000) Dopamine receptor partial agonists could address the duality of cocaine craving. Trend Pharmacol Sci21: 6–9.
11.
CitromeLJosiassenRBarkNSalazarDEMallikaarjunS (2005) Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol45: 89–93.
12.
Di Marino ME, Haberny KA, Felch LJ, Walsh SL, Preston KL and Bigelow GE (1998) Development of a subjective rating scale sensitive to acute cocaine administration. National Institute on Drug Abuse Research Monograph Series, Problems of Drug Dependence, 1997: Proceedings of the 59th Annual Scientific Meeting 178: 139.
13.
FeltensteinMWAltarCASeeRE (2007) Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry61: 582–590.
14.
FilipMPrzegalińskiE (1997) The role of dopamine receptor subtypes in the discriminative stimulus effects of amphetamine and cocaine in rats. Pol J Pharmacol49: 21–30.
15.
GarnerKJBakerLE (1999) Analysis of D2 and D3 receptor-selective ligands in rats trained to discriminate cocaine from saline. Pharmacol Biochem Behav64: 373–378.
HaneyMSpealmanR (2008) Controversies in translational research: drug self-administration. Psychopharmacology199: 403–419.
18.
HeishmanSJHenningfieldJE (1991) Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. Psychopharmacology103: 436–442.
19.
HughesAMLynchPRhodesJErvineCMYatesRA (1999) Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Br J Clin Pharmacol48: 323–330.
20.
InabaT (1989) Cocaine: pharmacokinetics and biotransformation in man. Can J Physiol Pharmacol67: 1154–1157.
21.
JasinskiD (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: MortonWRDrug Addiction INew York: Springer-Verlag.
22.
Jiménez-RuizCBerlinIHeringT (2009) Varenicline: a novel pharmacotherapy for smoking cessation. Drugs69: 1319–1338.
23.
KantakKMEdwardsMASpealmanRD (1995) Effects of N-methyl-D-aspartate antagonists in rats discriminating different doses of cocaine: comparison with direct and indirect dopamine agonists. J Pharmacol Exp Ther274: 657–665.
24.
KostenTADeCaprioJLNestlerEJ (1996) Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure. Psychopharmacology128: 304–312.
25.
LeDucPAMittlemanG (1993) Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology110: 427–436.
26.
LileJAStoopsWWHaysLRRushCR (2008) The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. Am J Drug Alcohol Abuse34: 721–729.
27.
LileJAStoopsWWVansickelARGlaserPEHaysLRRushCR (2005) Aripiprazole attenuates the discriminative-stimulus effects of d-amphetamine in humans. Neuropsychopharmacology30: 2103–2114.
28.
LiuYSunHQBaoYPLiSXBeveridgeTJDiXL (2009) Subjective, cognitive/psychomotor and physiological effects of aripiprazole in Chinese light and heavy smokers. Drug Alcohol Depend101: 42–52.
29.
McLeodDRGriffithsRRBigelowGEYinglingJE (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instr14: 463–466.
30.
MallikaarjunSSalazarDEBramerSL (2004) Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol44: 179–187.
31.
MallikaarjunSShoafSEBoultonDWBramerSL (2008) Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet47: 533–542.
32.
MartinWRSloanJWSapiraJDJasinskiDR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther12: 245–258.
33.
NaberDLambertM (2004) Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry28: 1213–1219.
34.
NewtonTFReidMSDe La GarzaRMahoneyJJAbadACondosR (2008) Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol11: 1037–1045.
35.
OlivetoAHBickelWKHughesJRSheaPJHigginsSTFenwickJW (1992) Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther261: 885–894.
36.
OlivetoAHRosenMIWoodsSWKostenTR (1995) Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans. J Pharmacol Exp Ther272: 231–241.
37.
OrmanJSKeatingGM (2009) Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs69: 577–607.
38.
PeltierRLEmmett-OglesbyMWThomasWHSchenkS (1994) Failure of ritanserin to block the discriminative or reinforcing stimulus effects of cocaine. Pharmacol Biochem Behav48: 473–478.
39.
PrzegaliñskiEFilipM (1997) Stimulation of serotonin (5-HT)1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats. Behav Pharmacol8: 699–706.
40.
PulvirentiLKoobGF (2002) Being partial to psychostimulant addiction therapy. Trends Pharmacol Sci23: 151–153.
41.
RushCRBakerRW (2001) Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp Clin Psychopharmacol9: 59–73.
42.
RushCRBakerRWWrightK (1999) Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis. Drug Alcohol Depend55: 1–12.
43.
RushCRKollinsSHPazzagliaPJ (1998) Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol6: 32–44.
44.
RushCRStoopsWWHaysLRGlaserPEAHaysLS (2003) Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther306: 195–204.
45.
SchamaKFHowellLLByrdLD (1997) Serotonergic modulation of the discriminative-stimulus effects of cocaine in squirrel monkeys. Psychopharmacology132: 27–34.
46.
SelzerML (1971) The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry127: 1653–1658.
47.
SevakRJStoopsWWHaysLRRushCR (2009) Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther328: 1007–1018.
48.
ShapiroDARenockSArringtonEChiodoLALiuLXSibleyDR (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology28: 1400–1411.
49.
SinnottRSMachRHNaderMA (1999) Dopamine D2/D3 receptors modulate cocaine's reinforcing and discriminative stimulus effects in rhesus monkeys. Drug Alcohol Depend54: 97–110.
50.
SkinnerHA (1982) The Drug Abuse Screening Test. Addict Behav7: 636–671.
51.
SmithBJJonesHEGriffithsRR (2001) Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology156: 435–444.
52.
SongMXuXHangTWenAYangL (2009) Development of an LC-MS/MS method for the simultaneous quantification of aripiprazole and dehydroaripiprazole in human plasma. Anal Biochem385: 270–277.
53.
SørensenGSagerTNPetersenJHBrennumLTThøgersenPHee BengtsenC (2008) Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Psychopharmacology199: 37–46.
54.
SotoPLKatzJL (2009) Fluoxetine does not alter the ability of dopamine D(1)- and D(2)-like agonists to substitute for cocaine in squirrel monkeys. Pharmacol Biochem Behav92: 219–223.
55.
SpealmanRD (1995) Discriminative stimulus effects of cocaine in squirrel monkeys: lack of antagonism by the dopamine D2 partial agonists terguride, SDZ 208-911, and SDZ 208-912. Pharmacol Biochem Behav51: 661–665.
56.
SpealmanRDBergmanJMadrasBKMeliaKF (1991) Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J Pharmacol Exp Ther258: 945–953.
57.
StoopsWWLileJAGlaserPERushCR (2006) A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend84: 206–209.
58.
StoopsWWLileJALofwallMRRushCR (2007) The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am J Drug Alcohol Abuse33: 769–776.
59.
SAMHSA (Substance Abuse and Mental Health Services Administration) (2009) Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434.
60.
ThomsenMFink-JensenAWoldbyeDPWörtweinGSagerTNHolmR (2008) Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats. Psychopharmacology201: 43–53.
61.
TiihonenJKuoppasalmiKFöhrJTuomolaPKuikanmäkiOVormaH (2007) A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry164: 160–162.
62.
Van DykeCJatlowPUngererJBarashPGByckR (1978) Oral cocaine: plasma concentrations and central effects. Science200: 211–213.
63.
VolkowNDWangGJFowlerJSLoganJGatleySJWongC (1999) Reinforcing effects of stimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. J Pharmacol Exp Ther291: 409–415.
64.
VoroninKRandallPMyrickHAntonR (2008) Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm – possible influence of self-control. Alcohol Clin Exp Res32: 1954–1961.
65.
WeeSWangZWoolvertonZPulvirentiLKoobGF (2007) Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology32: 2238–2247.
